Infectious Diseases Diagnostics Market

Infectious Diseases Diagnostics Market Outlook (2023 to 2033)

The global revenue from the Infectious Diseases Diagnostics Market was valued US$ 35.10 Billion in 2022, with the global market expected to grow at a CAGR of 4.2% to reach a valuation of US$ 55.16 Billion by the end of 2033.

As assessed by Persistence Market Research, respiratory infections held a market share of 33.60% in the global market in 2022. The global infectious diseases diagnostics market held 20% revenue share of the global clinical diagnostic market which was valued at US$ 157.68 million in 2022.

Sales Analysis of Market from 2013 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 7.3% in the last 9 years from 2013 to 2022.

Infectious diseases is fascinating and rapidly changing fields in medicine, with ongoing complex challenges. Since the incorporation of a vast array of methods based on various technologies, including molecular methods, FISH, mass spectrometry, RMN, immunoassays, and others, infection diagnosis has undergone a true transformation.

There is a significant disparity between global diagnostic access and diagnostic requirements, especially for infectious diseases that carry a heavy burden of morbidity and mortality. For proper patient care, accurate diagnostics are necessary. They also provide important data that support disease surveillance, prevention, and control strategies.

Digital molecular diagnostics blend point-of-care format, mobile connectivity, and the high sensitivity and specificity of molecular detection. Recent advancements in these technologies present a chance for the diagnostic ecosystem to undergo a fundamental change. Growing economies have the potential to set the standard for new healthcare delivery models centred on digital diagnostics rather than attempting to replicate diagnostic laboratory models in resource-rich environments.

The next generation of point-of-care tests has been made possible by advancements in digital molecular diagnostic technology. During the forecast period, this could spark changes in the way healthcare is delivered and increase demand for the product.

How Can the Global Market Grow?

"Rising Incidence of Infectious Diseases and Rising Focus on Evidence-based Medicine Before Treatment"

It has been observed that the prevalence of several infectious diseases is rising globally. Indications such as respiratory diseases and sexually transmitted infections are on the rise in countries all over the world.

• According to World Bank data, 37.7 million people globally are living with HIV in 2020, with women and girls accounting for half of those. Only 79% of female adults aged 15 and older had access to treatment, while only 68% of male adults did.

As a result, patients must be diagnosed for such infectious diseases, potentially increasing the infectious diseases diagnostic market.

Evidence-based medicine (EBM) is another important factor in healthcare environment because it allows clinicians to achieve higher quality, higher patient satisfaction, and lower costs.

EBM is more than just using evidence to develop treatment protocols; it also promotes conversation between patients and clinicians so that patients can participate in decision-making and express their values and preferences. As a result of physicians' emphasis on evidence-based diagnosis, diagnostics kits are in high demand.

The need for rapid test kits is increasing as more patients suffer from infectious diseases. The use of RDT testing has increased dramatically worldwide.

• According to the World Health Organization. 3.1 billion RDTs for malaria were sold worldwide in 2010–2020
• According to manufacturers contacted for the World Malaria Report 2021, around 81% of these sales going to sub-Saharan African nations. National malaria programmes distributed 2.2 billion RDTs during the same time, 88% of which went to sub-Saharan Africa.

“Reliable test kits with low-cost the of the products raise opportunities in the market.”

There are currently very few efficient diagnostic test kits for infectious illnesses. Cost-effective test kits with high specificity and sensitivity are required due to the lack of accessible diagnostic tools and the high cost of currently available test kits. As a result, businesses involved in this sector are currently concentrating on the creation of affordable and trustworthy test procedures. Additionally, expanding research and development efforts to produce highly accurate and sensitive diagnostic kits is anticipated to open up new business prospects for suppliers of diagnostic test kits for infectious diseases.

Different nations are concentrating on infectious illness prevention in order to lower their healthcare expenditures.

• For example, the Office of the Principal Scientific Adviser to the Government of India 2022 states that the India Health Fund, in collaboration with the Office of the Principal Scientific Adviser to the Government of India, is calling for innovations to address urgent issues affecting the control, treatment, and cure of infectious diseases.

This in turn present strong growth opportunities for suppliers of diagnostic kits for infectious diseases.

Can the Market Growth Be Affected in Any Way?

“High Cost of Infectious Diseases Diagnostic Products and Lack of Awareness of Diagnostic Kits”

Due to the vast number of market competitors selling diagnostic test kits, businesses are under intense pressure to lower their prices. The earnings of major international corporations are being impacted by the existence of several local manufacturers in APAC and Latin America.

• Wondfo launched its newest prequalified HIV self-test for US$1 EXW for public sector buyers in 140 low- and middle-income countries in accordance with the terms of the volume guarantee granted by MedAccess.

Rapid diagnostic test awareness is quite low in African nations, which makes it difficult for businesses to gain a foothold in the market. Similarly, a number of developing and underdeveloped nations rely on government funds to provide rapid diagnostic test kits in the event of an epidemic. Because of this, these nations have a less direct customer reach, which is impeding market expansion.

Country-wise Insights

Why is the United States Market Booming?

“Increased Demand for Infectious Diagnostic Test During the Pandemic”

The United States accounted for around 28.3% market share in the global market in 2022.

After the world was hit by the covid-19 pandemic, cases of people suffering from chronic diseases have increased, which has raised the demand for effective rapid medical diagnostic kits in the country. Several companies got involved in the development of rapid diagnostic tests for novel coronavirus, and are aiming to gain approval from the FDA to launch these tests in the U.S.

• For instance, in May 2020, an American diagnostic healthcare company named Quidel Corporation received Emergency Use Authorization (EUA) from the FDA for its new Sofia 2 SARS Antigen FIA for rapid diagnosis of covid-19.

Will the Japan Be a Lucrative Market for Infectious Diseases Diagnostics?

“Rising Incidence of Infectious Diseases in the Country”

The Japan market held around 8.5% share of the global market in 2022.

Japan has the third-largest economy in the world and a very high living standard. The citizens of Japan are entitled to free healthcare services. The use of Quick Navi - Flu2, a quick diagnostic kit for the detection of influenza viral antigen that is produced and marketed by Otsuka Pharmaceutical Co. Ltd. and Denka business Limited, was authorised by Japan's Ministry of Health, Labour, and Welfare in October 2020. As a result, the diagnostic for the infectious diseases is expanding.

How is China Emerging as a Prominent Market?

“Presence of Large Number of Key Manufacturers”

China held a market share of about 5.0% of the global market in 2022.

Due to its reputation as one of the sectors in China that is expanding the fastest, rapid medical diagnostics kits involve a large number of manufactures. The number of kits available in China that may be used to quickly and accurately diagnose a variety of ailments is also growing.

China has achieved progress in a number of important areas, including multiplexing, which is used to determine the results of many analyses simultaneously. For differential patient monitoring and diagnosis, profile test kits are employed.

Thus, these advances in China are facilitating the market to grow.

Will the Canada Be a Lucrative Market for Infectious Diseases Diagnostics Market?

“Growing Demand for Early Diagnosis”

The Canada market held around 4.7% market share of the global market in 2022.

The Public Health Agency of Canada (PHAC) reported that as of July 20, 2022, there were 604 cases of monkey pox. Similar to this, there is an increase in the use of advanced kits in laboratories to diagnose diseases from biological samples due to increased complexity of diseases and the need for early diagnosis. Infectious disease diagnostics will therefore be more in demand as a result of the increasing prevalence of various infectious disorders, which will ultimately fuel market expansion.

Category-wise Insights

Which Product Type is Leading in Infectious Diseases Diagnostics Market?

Kits and reagents accounted for a market share of 48.45% in 2022. This can be attributed to the high-volume usage of kits and reagents for conducting tests. Moreover, the COVID-19 testing programs to confirm positive, as well as negative tests, had escalated the usage of kits and reagents.

Which Test Type is Driving Demand within the Global Market?

“Rapid and proper test findings of the diagnostic test is fuelling the market.”

The diagnostic test held around 67.88% of market share of the global market in 2022.

Rapid molecular diagnostic methods for infectious diseases offer quicker diagnostic test findings and, when properly applied, will speed up patient care delivery. Understanding the individual test performance benefits and limitations is therefore necessary for the proper clinical implementation of test diagnoses, and this is best achieved through diagnostic test.

Which Application is Adopted within the Global Market?

“Rising Prevalence of Respiratory Illnesses.”

Respiratory infection held around 33.60% of the market share in the global market in 2022. The elevated use of SARS-CoV-2 testing to limit the infection's spread is responsible for the segment's high market share.

• According to the Centers for Disease Control and Prevention (CDC), the US is experiencing a flu epidemic in 2022. As cases grow and new varieties emerge, the country also confronts a triple epidemic of the flu, respiratory syncytial virus (RSV) in young children, and covid–19. The CDC estimates that at least 1 600 000 illnesses, 13 000 hospital admissions, and 730 flu–related fatalities have occurred so far this season.

Which End User is Widely Adopted for infectious Disease Diagnostics?

“Hospitals With Skilled Staff and High-Quality Results Will Dominate the Market Segment.”

Hospitals held around 48.7% of share of the total market in 2022.

Hospitals plays a critical role in disease management. It aids in the precise identification of illnesses or other ailments, and with the help of this information, the doctor can select a particular course of therapy. Hospitals have the appropriate laboratory apparatus, skilled workers, and medical specialists to help diagnose diseases in patients exhibiting particular symptoms or indicators. These reasons are making hospitals more popular in the marketplace.

Competition Landscape

Manufacturers are focused on developing high-quality diagnostic test kits with lower pricing, thus expecting to increase their respective market shares. Similarly, manufacturers are focusing on creating awareness about infectious diseases through social campaigns in order to increase demand for their diagnostic test kits.

Some key instances of development include:

• On May 14, 2022, Myriad Genetics, Inc., a pioneer in genetic testing and precision medicine, announced the introduction of Precisce Oncology Solutions, a comprehensive solution created to assist oncologists in developing efficient and individualised treatment regimens for specific patients.
• BioMérieux and BrightInsight, Inc., announced a partnership on September 21, 2022, to create and commercialise a Medical Virtual Solution for diagnostics that will enable clinical decision assistance for diseases across their diagnostics.

Infectious Diseases Diagnostics Industry Report Scope

Key Segments Covered in Infectious Diseases Diagnostics Industry Research

Product:

• Instrument
  • Biochips
  • Microfluidics Based POCT
  • DNA Microarrays
  • Mass Spectrometry
  • Real-time Polymerase Chain Reaction (qPCR)
  • Fluorescence in situ Hybridization (FISH)
  • Sequencing
    • Capillary Electrophoresis
    • Next Generation Sequencing

• Kits and reagents
  • Kits
  • Primary antibodies
  • Secondary antibodies
  • Substrates
  • Buffers
• consumables

Test Type:

• Screening Test
• Diagnostic Test

Application:

• Hospital- Acquired Infections
• Sexually Transmitted Disease (STD)
• Sepsis
• Meningitis
• Respiratory Infections
• HPV
• Gastrointestinal Tract Infections
• Infection in Transplant Patients
• Hepatitis B and C
• Tuberculosis
• Others

End User:

• Hospitals
• Diagnostic Laboratories
• Clinics
• Academic and Research Institutes
• Others

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

To know more about delivery timeline for this report Contact Sales